Also listed on Horizon Pharma Rheumatology LLC, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jun 25, 2030 · High confidence
20-year base term ends Jun 25, 2030
Held by Horizon Therapeutics Ireland Dac
Filed Aug 8, 2012 as application 13/379,704 · Granted Jun 28, 2016
Base term, 20 years from filing
Today
2010
2030
Clock starts
Jun 25, 2010
Jun 25, 2010
Term ends
Jun 25, 2030
Jun 25, 2030
Granted
Jun 28, 2016
Jun 28, 2016
base term
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 25, 2010, when application PCT/US2010/040082, the earliest non-provisional in its chain, was filed (this one was filed Aug 8, 2012) | Jun 25, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 25, 2030 | High confidence |
Partial family
| Application PCT/US2010/004008 | PCT application no patent term | no patent term |
| Application PCT/US2010/040082 | PCT application no patent term | no patent term |
| US 9,377,454 | this patent Jun 2030 | Jun 2030 |
| Application 15/165,318 | Abandoned not computed | not computed |
| US 10,139,399 | In force Jun 2030 | Jun 2030 |
| US 10,823,727 | In force Jun 2030 | Jun 2030 |
| US 11,639,927 | In force Jun 2030 | Jun 2030 |
| US 11,598,767 | In force Jun 2030 | Jun 2030 |
8 of 13 applications in this family shown, earliest filings first. Partial: 1 of the 13 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 12, 2012 Reel 28363, frame 40 | Savient Pharmaceuticals, Inc. | Morgan Stanley Senior Funding Inc. | Security Agreement |
| Aug 3, 2012 Reel 28715, frame 585 | Rosario-jansen, Theresa; Wright, David Erick | Savient Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jul 23, 2013 Reel 30936, frame 72 | Savient Pharmaceuticals, Inc. | U.S. National Bank Association, as Collateral Agent | Corrective Assignment to Correct the Receiving Party Previously Recorded on Reel 028363 Frame 0040. Assignor(S) Hereby Confirms the Security Agreement. |
| Feb 21, 2014 Reel 32319, frame 77 | Crealta Pharmaceuticals LLC | Jefferies Finance LLC, as Collateral Agent | Security Agreement |
| Apr 15, 2014 Reel 32675, frame 936 | Savient Pharmaceuticals, Inc.; Savient Pharma Holdings, LLC | Crealta Pharmaceuticals LLC | Assignment of Assignor's Interest |
| Jan 13, 2016 Reel 37483, frame 49 | Fifth Street Finance Corp., as Collateral Agent | Crealta Pharmaceuticals LLC | Release of Security Interest |
| Jan 13, 2016 Reel 37483, frame 148 | Jefferies Finance LLC, as Collateral Agent | Crealta Pharmaceuticals LLC | Release of Security Interest |
| Sep 16, 2016 Reel 40059, frame 7 | Horizon Pharma Rheumatology LLC (Formerly Known as Crealta Pharmaceuticals LLC) | Citibank, N.A., as Collateral Agent | Patent Security Agreement |
| Nov 18, 2016 Reel 40648, frame 361 | Crealta Pharmaceuticals LLC | Horizon Pharma USA Rheumatology LLC | Change of Name |
| Nov 18, 2016 Reel 40648, frame 367 | Horizon Pharma USA Rheumatology LLC | Horizon Pharma Rheumatology LLC | Change of Name |
| Oct 31, 2022 Reel 61805, frame 76 | Horizon Pharma Rheumatology LLC | Horizon Therapeutics USA, Inc. | Assignment of Assignor's Interest |
| Dec 1, 2022 Reel 62073, frame 930 | Horizon Pharma Rheumatology LLC | Horizon Therapeutics USA, Inc. | Corrective Assignment to Correct the Name of the Assignee Previously Recorded on Reel 061805 Frame 0076. Assignor(S) Hereby Confirms the Assignment. |
| Jun 16, 2023 Reel 64009, frame 261 | Savient Pharmaceuticals, Inc.; Savient Pharma Holdings, Inc. | Crealta Pharmaceuticals LLC | Corrective Assignment to Correct the Seller's Name and Execution Date Previously Recorded on Reel 032675 Frame 0936. Assignor(S) Hereby Confirms the Seller's Name Should Read Savient Pharma Holdings, Inc. and the Execution Date for Both Parties Should Read 01/09/2014. |
| Oct 6, 2023 Reel 65178, frame 965 | Citibank, N.a. | Horizon Therapeutics USA, Inc. | Release of Security Interest |
| Nov 6, 2026 Reel 76662, frame 840 | Horizon Therapeutics USA, Inc. | Horizon Therapeutics Ireland Dac | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jun 2030
Term ends Jun 25, 2030. Maintenance fees still fall due before then
Citations
46
later US patents cite this one
That is top 10% of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.